What is Reshape Lifesciences Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Reshape Lifesciences's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Reshape Lifesciences's Operating Income for the
three
months ended in Dec. 2023 was $ -1.90 Mil. Reshape Lifesciences's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
GuruFocus does not calculate Reshape Lifesciences's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Reshape Lifesciences Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reshape Lifesciences (OTCPK:RSLS) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Reshape Lifesciences's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-1.90 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $0.15 Mil.
Reshape Lifesciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate Reshape Lifesciences's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Reshape Lifesciences (Reshape Lifesciences) Business Description
Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Executives
| Thomas Stankovich |
officer: Chief Financial Officer |
1001 CALLE AMANECER, SAN CLEMENTE CA 92673 |
| Barton P. Bandy |
officer: President and CEO |
1001 CALLE AMANECER, SAN CLEMENTE CA 92673 |
| Dan W Gladney |
director, officer: Chairman, President and CEO |
2800 PATTON ROAD, ST. PAUL MN 55113 |
| Armistice Capital, Llc |
10 percent owner |
510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| Armistice Capital Master Fund Ltd. |
10 percent owner |
C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| Steven Boyd |
10 percent owner |
510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| Sabby Management, Llc |
10 percent owner |
115 HIDDEN HILLS DR, SPICEWOOD TX 78669 |
| Arda Phd Minocherhomjee |
director |
C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606 |
| Scott P Youngstrom |
officer: CFO and SVP, Finance |
2800 PATTON ROAD ST. PAUL MN 55113 |
| Joseph Patrick Healey |
10 percent owner |
31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001 |
| Healthcor Partners Ii, L.p. |
10 percent owner |
152 W. 57TH STREET, 43RD FLOOR NEW YORK NY 10019 |
| Michael Y Mashaal |
director |
309 WAVERLEY OAKS RD., SUITE 105 WALTHAM MA 02452 |
| Healthcor Partners Fund Ii, L.p. |
10 percent owner |
CARNEGIE HILL TOWER 152 WEST 57TH STREET, 43RD FLOOR NEW YORK NY 10019 |
| Jeffrey C Lightcap |
10 percent owner |
152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019 |
| Healthcor Partners Management Gp, Llc |
10 percent owner |
152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019 |
Reshape Lifesciences (Reshape Lifesciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RSLS has been successfully added to your 